


Disclosures

No relevant financial relationship(s) with industry:

I do intend to discuss off-label / investigative uses(s) of the following commercial product(s)/devices(s):

Gadolinium for Cardiovascular MRI






Multimodality Cardiac Imaging: Objectives

Learning Goals:

- Discuss the relative strengths and weaknesses of various imaging modalities for cardiac imaging
- Use those strengths & weaknesses to guide management decisions regarding the use of appropriate cardiac imaging modality

✓ Head-to-head comparison of CT & MRI





Nucs

VS

CT

VS

MRI

Pros:

- Highest contrast sensitivity
- Most published data
- Widely

Pros:

- Better spatial resolution
- Visualize calcification

Pros:

- Tissue characterization
- High contrast sensitivity
- Flow information

All are highly dependent on available technology and local expertise

Cons:

- Radiation
- Less spatial resolution
- Less tissue discrimination

- Radiation
- Less contrast sensitivity
- No flow information

- Most operator dependent
- More expensive
- Cardiac devices



Cardiac Nuclear Medicine: Exam Basics

Radionuclide testing

- 99mTc-sestamibi & 201Thallium+ (SPECT)
- 18F-FDG (PET)

Traditional role

- Acute coronary syndromes
- Chronic coronary disease

Emerging role

Novel radiotracers – targeted at specific diseases

ACC/AHA Guideline

ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging—Executive Summary

A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging)

Committee Members

Francis J. Klocke, MD, MACC, FAHA, Chair;
Michael G. Baird, MD, FACC, FAHA; Beverly H. Lorell, MD, FACC, FAHA;
Timothy M. Bateman, MD, FACC, FAHA; Joseph V. Messer, MD, MACC, FAHA;
Daniel S. Berman, MD, FACC, FAHA; Patrick T. O'Gara, MD, FACC;
Blase A. Carabello, MD, FACC, FAHA; Richard O. Russell, Jr, MD, FACC;
Manuel D. Cerqueira, MD, FACC, FAHA; Martin G. St. John Sutton, MBBS, FACC;
Anthony N. DeMaria, MD, MACC, FAHA; James E. Udelson, MD, FACC;
J. Ward Kennedy, MD, MACC, FAHA; Mario S. Verani, MD, FACC*;
Kim Allan Williams, MD, FACC, FAHA

Task Force Members

Elliott M. Antman, MD, FACC, FAHA, Chair; Sidney C. Smith, Jr, MD, FACC, FAHA, Vice-Chair; Joseph S. Alpert, MD, FACC; Gabriel Gregoratos, MD, FACC, FAHA; Jeffrey L. Anderson, MD, FACC; Loren F. Hiratzka, MD, FACC, FAHA; David P. Faxon, MD, FACC, FAHA; Sharon Ann Hunt, MD, FACC, FAHA; Valentin Fuster, MD, PhD, FACC, FAHA; Alice K. Jacobs, MD, FACC, FAHA; Raymond J. Gibbons, MD, FACC, FAHA†; Richard O. Russell, MD, FACC†

Table of Contents

- and Assessment of Therapy After NSTEMI or UA, 1406

 I. Chronic Syndromer. 1407

Science Advisory and Coordinating Committee in July, 2003, and the American Society of Nuclear Cardiology Board of Directors in July, 2003. When citing this document, the American College of Cardiology Foundation, the American Heart Association, and the American Society of Nuclear Cardiology request that the following citation format be used: Rocket FJ, Baird MG, Baternan TM, Berman DS, Carabello BA, Cerqueira MD, DeMaria AN, Kennedy JW, Lorell BH, Messer JV, O'Gara PT, Russell RO Jr, St. John Sutton MG, Udelson JE, Verani MS, Williams KA, ACC/AHA/ASNC guidelines for the clinical use of cardio-radionuclide imaging—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Radionuclide Imaging). (Circulation. 2003) (1891:1404–1418.)

*Deceased. †Former Task Force Member.

‡Former Task Force Chair.

(Circulation 2003;108:1404-1418.)


©2003 by the American College of Cardiology Foundation and the American Heart Association, Inc.

Circulation is available at http://www.circulationaha.org DOI: 10.1161/01.CIR.0000080946.42225.4D



The ACC/AHA Task Force on Practice Guidelines makes every effort to avoid any actual or potential conflicts of interest that might arise as a result of an outside relationship or personal interest of a member of the writing panel are saked to provide disclosure statements of all such relationships that might be perceived as real or potential conflicts of interest. These statements are reviewed by the parent task force, reported orally to all members of the writing panel at the first meeting, and updated as changes occur. This document was approved by the American College of Cardiology Foundation Board of Trustees in July, 2003, the American Heart Association


Cardiac Nuclear Medicine: Exam Basics







Cardiac Nuclear Medicine: Exam Basics







Cardiac Nuclear Medicine: Summary

Evolving role in cardiac imaging

- Traditional noninvasive test of choice for diagnosis and prognosis in coronary artery disease
- Increasing role in delineation of causes of heart failure – particularly due to rise of novel radiotracers
- Frequently used in conjunction with cardiac CT and MRI – not a competitor in terms of direct imaging of the heart

ACC/AHA Guideline

ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging—Executive Summary

A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging)

Committee Members

Francis J. Klocke, MD, MACC, FAHA, Chair;
Michael G. Baird, MD, FACC, FAHA; Beverly H. Lorell, MD, FACC, FAHA;
Timothy M. Bateman, MD, FACC, FAHA; Joseph V. Messer, MD, MACC, FAHA;
Daniel S. Berman, MD, FACC, FAHA; Patrick T. O'Gara, MD, FACC;
Blase A. Carabello, MD, FACC, FAHA; Richard O. Russell, Jr, MD, FACC;
Manuel D. Cerqueira, MD, FACC, FAHA; Martin G. St. John Sutton, MBBS, FACC;
Anthony N. DeMaria, MD, MACC, FAHA; James E. Udelson, MD, FACC;
J. Ward Kennedy, MD, MACC, FAHA; Mario S. Verani, MD, FACC*;
Kim Allan Williams, MD, FACC, FAHA

Task Force Members

Elliott M. Antman, MD, FACC, FAHA, Chair; Sidney C. Smith, Jr, MD, FACC, FAHA, Vice-Chair; Joseph S. Alpert, MD, FACC; Gabriel Gregoratos, MD, FACC, FAHA; Jeffrey L. Anderson, MD, FACC; Loren F. Hiratzka, MD, FACC, FAHA; David P. Faxon, MD, FACC, FAHA; Sharon Ann Hunt, MD, FACC, FAHA; Valentin Fuster, MD, PhD, FACC, FAHA; Alice K. Jacobs, MD, FACC, FAHA; Raymond J. Gibbons, MD, FACC, FAHA†‡; Richard O. Russell, MD, FACC†

Table of Content

- and Assessment of Therapy After NSTEMI or UA, 1406

The ACC/AHA Task Force on Practice Guidelines makes every effort to avoid any actual or potential conflicts of interest that might arise as a result and of an outside relationship or personal interest of a member of the writing panel. Specifically, all members of the writing panel are asked to produce disclosure statements of all such relationships that might be perceived as real or potential conflicts of interest. These statements are reviewed by the parent task frorce, reported or ally to all members of the writing panel at the first meeting, and updated as changes occur.

This document was approved by the American College of Cardiology Foundation Board of Trustees in July, 2003, the American Heart Association. Science Advisory and Coordinating Committee in July, 2003, and the American Society of Nuclear Cardiology Board of Directors in July, 2003. When citing this document, the American College of Cardiology Foundation, the American Heart Association, and the American Society of Nuclear Cardiology Repuest that the following citation format be used: Nocle-EF, Baird MG, Bateman TM, Berman DS, Carabellor AN, Cerquieris MD, DeMaria AN, Kennedy JW, Lorell BH, Messer JV, O'Gara PT, Russell RO Jr, St. John Sutton MG, Udelson JE, Verani MS, Williams KA, ACC/AHA/ASSNC guidelines for the clinical use of cardiac radionuclide imaging—accurate variety are prot of the American College of Cardiogy/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Radionuclide Imaging). (Circulation. 2003; 1084:1041–1418).

*Deceased. †Former Task Force Memb


†Former Task Force Member. ‡Former Task Force Chair.

(Circulation 2003;108:1404-1418.)

©2003 by the American College of Cardiology Foundation and the American Heart Association. Inc.

Circulation is available at http://www.circulationaha.org DOI: 10.1161/01.CIR.0000080946.42225.4D







Key Facts

Uses radiation

IV contrast(variable)





Key Facts

Uses radiation

IV contrast
 (variable)





Key Facts

Uses radiation

IV contrast
 (variable)







Key Facts

Uses radiation

IV contrast
 (variable)

ECG-gating








Key Facts

Uses radiation

IV contrast
 (variable)

ECG-gating












Can't Gate = Not Great



Spatial Resolution – Coronary Arteries





Submillimeter spatial resolution

...assuming ECG-gating is working



Spatial Resolution – Aortic Root









Calcification – Coronary arteries, valves, pericardium, etc...










Cardiac CT: Modality Strengths











MAYO CLINIC

Cardiac Magnetic Resonance Imaging



Key Facts

Uses magnet
Always on





Key Facts

Uses magnet
Always on



Key Facts

Uses magnet
Tight space

Claustrophobia





Key Facts

Uses magnet

IV contrast (variable)

ECG-gating








No Gate = No Good



Contrast Enhancement – Pericardium

44 y/o ♂:


Echo:
 indeterminate
 findings for
 constrictive
 physiology





Tissue Characterization – Myocardium









Tissue Characterization – Cardiac Masses









Contrast Enhancement – Cardiac Masses









Cardiac MRI: Modality Strengths







MRI = best test for tissue characterization & enhancement




Multimodality Imaging Comparison




The patient rather than the disease will often dictate the modality



CT vs MRI: Pericardial Disease




If patient is **young** and/or **female**, consider MRI




If patient is a poor breath holder, consider CT



CT vs MRI: Pericardial Disease




If patient is **cooperative**, consider MRI




If patient is sick or can't hold still, consider CT

CT vs MRI: Myocardial Infarction




Echo: apical MI? thrombus






CT vs MRI: Cardiac Masses






Multimodality Imaging Comparison





CT vs MRI: Flow Information






Flow information not available from CT

CT vs MRI: Cardiac Devices








...if patient has a device, you may not care

CT vs MRI: Calcification & PO Changes

Left AV groove mass seen at echocardiography









Calcification not visible on MRI

CT vs MRI: Calcification & PO Changes

Findings on echocardiography suspicious for pericardial constriction







Calcification not visible on MRI

Multimodality Cardiac Imaging: Summary

Cardiac Nucs


 Perfusion imaging for coronary artery disease. Novel radiotracers for specific disease entities.

Cardiac CT

Best test for visualizing coronary arteries and calcium.

Cardiac MRI

 Best test for tissue characterization & myocardial / pericardial enhancement.



Sometimes the patient will dictate the modality rather than the disease



